Somayeh Shahrokhi

Somayeh Shahrokhi

Auto-generated profile, based on publicly available information

Somayeh Shahrokhi

Department of Immunology, Lorestan University of Medical Sciences, Khorramabad, Iran

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in International Immunopharmacology
Verified
Journal Article
Closed access
AMAdel Mohammadzadeh
Adel Mohammadzadeh
APAli Akbar Pourfathollah
Ali Akbar Pourfathollah
SSSomayeh Shahrokhi
Somayeh Shahrokhi
SHSeyed Mahmoud Hashemi
Seyed Mahmoud Hashemi
SMSadegh Lotf Alah Moradi
Sadegh Lotf Alah Moradi
MSMasoud Soleimani
Masoud Soleimani

21 May 2019 in Drug Delivery and Translational Research
Verified
Journal Article
Closed access
PDF file
FAFatemeh Ashouri
Fatemeh Ashouri
FBFatemeh Beyranvand
Fatemeh Beyranvand
NBNasim Beigi Boroujeni
Nasim Beigi Boroujeni
MTMajid Tavafi
Majid Tavafi
ASAli Sheikhian
Ali Sheikhian
SSSomayeh Shahrokhi
Somayeh Shahrokhi

1 August 2016 in Clinical Immunology
Verified
Journal Article
Closed access
AMAdel Mohammadzadeh
Adel Mohammadzadeh
APAli Akbar Pourfathollah
Ali Akbar Pourfathollah
SSSomayeh Shahrokhi
Somayeh Shahrokhi
AFAli Fallah
Ali Fallah
MTMohammad Taher Tahoori
Mohammad Taher Tahoori
MSMasoud Soleimani
Masoud Soleimani

9 October 2013 in Human Gene Therapy
Verified
Journal Article
Open access
SSSomayeh Shahrokhi
Somayeh Shahrokhi
SDSaeed Daneshmandi
Saeed Daneshmandi
Farid MenaaFarid Menaa
Farid Menaa
The interaction between mesenchymal stem cells (MSCs) and dendritic cells (DCs) affects T cell development and function. Further, the chemotactic capacity of MSCs, their interaction with the tumor microenvironment, and the intervention of immune-stimulatory molecules suggest possible exploitation of tumor necrosis factor-α ( TNF-α ) and CD40 ligand ( CD40L ) to genetically modify MSCs for enhanced cancer therapy. Both DCs and MSCs were isolated from BALB/c mice. DCs were then cocultured with MSCs transduced with TNF-α and/or CD40L [ (TNF-α/CD40L) -MSCs]. Major DCs' maturation markers, DC and T cell cytokines such as interleukin-4, -6, -10, -12, TNF-α, tumor growth factor-β, as well as T cell proliferation, were assessed. Meantime, a BALB/c mouse breast tumor model was inducted by injecting 4T1 cells subcutaneously. Mice ( n =10) in each well-defined test groups ( n =13) were cotreated with DCs and/or ( TNF-α/CD40L )-MSCs. The controls included untreated, empty vector-MSC, DC-lipopolysaccharide, and immature DC mouse groups. Eventually, cytokine levels from murine splenocytes, as well as tumor volume and survival of mice, were assessed. Compared with the corresponding controls, both in vitro and in vivo analyses showed induction of T helper 1 ( Th1 ) as well as suppression of Th2 and Treg responses in test groups, which led to a valuable antitumor immune response. Further, the longest mouse survival was observed in mouse groups that were administered with DCs plus ( TNF-α/CD40L )-MSCs. In our experimental setting, the present pioneered study demonstrates that concomitant genetic modification of MSCs with TNF-α and CD40L optimized the antitumor immunity response in the presence of DCs, meantime increasing the mouse lifespan.

31 October 2012 in Journal of Biomedicine and Biotechnology
Verified
Journal Article
Open access
PDF file
SSSomayeh Shahrokhi
Somayeh Shahrokhi
Farid MenaaFarid Menaa
Farid Menaa
KAKamran Alimoghaddam
Kamran Alimoghaddam
CMColin McGuckin
Colin McGuckin
MEMasoumeh Ebtekar
Masoumeh Ebtekar
Over 20.000 umblical cord blood transplantations (UCBT) have been carried out around the world. Indeed, UCBT represents an attractive source of donor hematopoietic stem cells (HSCs) and, offer interesting features (e.g., lower graft-versus-host disease) compared to bone marrow transplantation (BMT). Thereby, UCBT often represents the unique curative option against several blood diseases. Recent advances in the field of UCBT, consisted to develop strategies to expand umbilical stem cells and shorter the timing of their engraftment, subsequently enhancing their availability for enhanced efficacy of transplantation into indicated patients with malignant diseases (e.g., leukemia) or non-malignant diseases (e.g., thalassemia major). Several studies showed that the expansion and homing of UCBSCs depends on specific biological factors and cell types (e.g., cytokines, neuropeptides, co-culture with stromal cells). In this review, we extensively present the advantages and disadvantages of current hematopoietic stem cell transplantations (HSCTs), compared to UBCT. We further describe the importance of cord blood content and obstetric factors on cord blood selection, and report the recent approaches that can be undertook to improve cord blood stem cell expansion as well as engraftment. Eventually, we provide two majors examples underlining the importance of UCBT as a potential cure for blood diseases.

1 June 2005 in International Immunopharmacology
Verified
Journal Article
Closed access
AAArdeshir Abbasi
Ardeshir Abbasi
RFReza Feyzi
Reza Feyzi
ASAli Sheikhian
Ali Sheikhian
ABAfshar Bargahi
Afshar Bargahi
AMAli Mostafaie
Ali Mostafaie
SSShahram Shahabi
Shahram Shahabi